In June, the American Medical Association's (AMA) president Barbara L. McAneny, MD, outlined the group’s concerns during a hearing held by the California Department of Insurance stating that “The AMA has come to the conclusion that this merger would likely substantially lessen competition in many healthcare markets, to the detriment of patients,” and therefore should be blocked.
Earlier this week the Department of Justice (DOJ) cleared the $69 billion merger between CVS and Aetna, with some conditions.
In order to approve the merger, the DOJ required Aetna to sell off its Medicare Part D business, worth $2.2 million, as CVS already has its own Part D business under its “SilverScript” brand. Antitrust regulators stated that this would “fully resolve the departments anticompetitive concerns,” and, in agreement, Aetna will sell off its Part D business to WellCare.
“The divestitures required here allow for the creation of an integrated pharmacy and health benefits company that has the potential to generate benefits by improving the quality and lowering the costs of the healthcare services that American consumers can obtain,” said assistant attorney general Makan Delrahim of the Justice Department’s AntiTrust Division in a statement.
Without the divestiture, DOJ attorneys argued that the combined company would have anticompetitive effects, increased prices, and inferior customer service, specifically in the states where Aetna previously sold Part D plans.
“DOJ clearance is an important step toward bringing together the strengths and capabilities of our two companies to improve the consumer healthcare experience. We are pleased to have reached an agreement with the DOJ that maintains the strategic benefits and value creation potential of our combination with Aetna,” said CVS Health president and CEO, Larry J. Merlo in a statement.
However, notable industry members such as the American Medical Association (AMA) and the American Antitrust Institute (AAI) have spoken out against the merger and called for the DOJ to block the transaction prior to its announcement this week.
In June, AMA president Barbara L. McAneny, MD, outlined the group’s concerns during a hearing held by the California Department of Insurance stating that “The AMA has come to the conclusion that this merger would likely substantially lessen competition in many healthcare markets, to the detriment of patients,” and therefore should be blocked.
While part of the AMA’s concern was resolved with the DOJ requirement that Aetna sell off its Part D business, other factors remain such as the anticompetitive effects the merger would have on pharmacy benefit manager (PBM) services, health insurance, retail pharmacy, and specialty pharmacy. AAI echoed these concerns citing its belief that 3 integrated PBM-insurer systems would dominate the marketplace and effectively lock out competition.
Going forward, CVS and Aetna are working to complete the remaining state reviews, and CVS believes the merger is on track to be completed in the early part of this quarter.
Partnering for Biosimilar Security: India's Role in US Health Care Savings, Supply Chain Stability
May 9th 2024As Indian pharmaceutical companies supplied 4 of every 10 prescriptions in the US in 2022, generating $1.3 trillion in health care savings, a new IQVIA report highlights concerns about supply chain risks and advocates for partnerships to bolster biosimilar security and overall supply chain resilience.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.